Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's

Autoimmunity Reviews

Volumn 16, Issue 11, 2017, Pages 1103-1108

  Arnaud, Laurent ^a   Conti, Fabrizio ^b   Massaro, Laura ^b   Denas, Gentian ^c   Chasset, François ^d   Pengo, Vittorio ^c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Antiphospholipid antibodies; Aspirin; Primary prophylaxis; Systematic review; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIBODY TITER; ASYMPTOMATIC DISEASE; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; OBSERVATIONAL STUDY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; ANTIPHOSPHOLIPID SYNDROME; COMPLICATION; PROGNOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; HUMANS; PROGNOSIS; THROMBOSIS;

EID: 85029424413     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.09.003     Document Type: Review

References (51)

1. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
2. Pierangeli, S.S., Favaloro, E.J., Lakos, G., Meroni, P.L., Tincani, A., Wong, R.C., et al. Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th international congress on antiphospholipid antibodies. Clin Chim Acta 413 (2011), 358–360.
3. Shi, W., Krilis, S.A., Chong, B.H., Gordon, S., Chesterman, C.N., Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 20 (1990), 231–236.
4. Vila, P., Hernandez, M.C., Lopez-Fernandez, M.F., Batlle, J., Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72 (1994), 209–213.
5. Barbhaiya, M., Erkan, D., Primary thrombosis prophylaxis in antiphospholipid antibody positive patients: where do we stand?. Curr Rheumatol Rep 13 (2011), 59–69.
6. Yelnik, C.M., Urbanski, G., Drumez, E., Sobanski, V., Maillard, H., Lanteri, A., et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus, Jul 17 2016 pii: 0961203316657433. [Epub ahead of print].
7. Brouwer, J.L., Bijl, M., Veeger, N.J., Kluin-Nelemans, H.C., van der Meer, J., The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 104 (2004), 143–148.
8. Shah, N.M., Khamashta, M.A., Atsumi, T., Hughes, G.R., Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7 (1998), 3–6.
9. Ruiz-Irastorza, G., Crowther, M., Branch, W., Khamashta, M.A., Antiphospholipid syndrome. Lancet 376 (2010), 1498–1509.
10. Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218.
11. Ridker, P.M., Cook, N.R., Lee, I.M., Gordon, D., Gaziano, J.M., Manson, J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005), 1293–1304.
12. Saito, Y., Okada, S., Ogawa, H., Soejima, H., Sakuma, M., Nakayama, M., et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation 135 (2017), 659–670.
13. Raju, N., Sobieraj-Teague, M., Hirsh, J., O'Donnell, M., Eikelboom, J., Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 124 (2011), 621–629.
14. Berger, J.S., Roncaglioni, M.C., Avanzini, F., Pangrazzi, I., Tognoni, G., Brown, D.L., Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006), 306–313.
15. Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 13 (2014), 281–291.
16. Arnaud, L., Mathian, A., Devilliers, H., Ruffatti, A., Tektonidou, M., Forastiero, R., et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 14 (2015), 192–200.
17. Wahl, D.G., Bounameaux, H., de Moerloose, P., Sarasin, F.P., Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160 (2000), 2042–2048.
18. Ruffatti, A., Del Ross, T., Ciprian, M., Bertero, M.T., Sciascia, S., Scarpato, S., et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 70 (2011), 1083–1086.
19. Giron-Gonzalez, J.A., Garcia del Rio, E., Rodriguez, C., Rodriguez-Martorell, J., Serrano, A., Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31 (2004), 1560–1567.
20. Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56 (2007), 2382–2391.
21. Cuadrado, M.J., Bertolaccini, M.L., Seed, P.T., Tektonidou, M.G., Aguirre, A., Mico, L., et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) 53 (2014), 275–284.
22. Moulis, G., Audemard-Verger, A., Arnaud, L., Luxembourger, C., Montastruc, F., Gaman, A.M., et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis. Autoimmun Rev 15 (2016), 203–209.
23. Posch, F., Gebhart, J., Rand, J.H., Koder, S., Quehenberger, P., Pengo, V., et al. Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Med, 15, 2017, 54.
24. Parodis, I., Arnaud, L., Gerhardsson, J., Zickert, A., Sundelin, B., Malmstrom, V., et al. Antiphospholipid antibodies in lupus nephritis. PLoS One, 11, 2016, e0158076.
25. Galli, M., Luciani, D., Bertolini, G., Barbui, T., Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102 (2003), 2717–2723.
26. Reynaud, Q., Lega, J.C., Mismetti, P., Chapelle, C., Wahl, D., Cathebras, P., et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13 (2014), 595–608.
27. Mustonen, P., Lehtonen, K.V., Javela, K., Puurunen, M., Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 23 (2014), 1468–1476.
28. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718.
29. Domingues, V., Magder, L.S., Petri, M., Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med, 3, 2016, e000107.
30. Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8 (2010), 237–242.
31. Otomo, K., Atsumi, T., Amengual, O., Fujieda, Y., Kato, M., Oku, K., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64 (2012), 504–512.
32. Kelchtermans, H., Pelkmans, L., de Laat, B., Devreese, K.M., IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 14 (2016), 1530–1548.
33. Meijide, H., Sciascia, S., Sanna, G., Khamashta, M.A., Bertolaccini, M.L., The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 12 (2013), 421–425.
34. Ruffatti, A., Olivieri, S., Tonello, M., Bortolati, M., Bison, E., Salvan, E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 6 (2008), 1693–1696.
35. de Groot, P.G., Urbanus, R.T., The significance of autoantibodies against beta2-glycoprotein I. Blood 120 (2012), 266–274.
36. de Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7 (2009), 1767–1773.
37. Iwaniec, T., Kaczor, M.P., Celinska-Lowenhoff, M., Polanski, S., Musial, J., Clinical significance of anti-domain 1 beta2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res 153 (2017), 90–94.
38. Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., et al. Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13 (2015), 782–787.
39. Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., et al. Antibodies to domain 4/5 (Dm4/5) of beta2-glycoprotein 1 (beta2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res 136 (2015), 161–163.
40. Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M.A., Bertolaccini, M.L., Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111 (2014), 354–364.
41. Wolgast, L.R., Arslan, A.A., Wu, X.X., Niakan, J., Pengo, V., Rand, J.H., Reduction of Annexin A5 anticoagulant ratio identifies Antiphospholipid antibody-positive patients with adverse clinical outcomes. J Thromb Haemost 15:7 (2017 Jul), 1412–1421.
42. Ortona, E., Capozzi, A., Colasanti, T., Conti, F., Alessandri, C., Longo, A., et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 116 (2010 Oct), 2960–2967.
43. Asanuma, Y., Oeser, A., Shintani, A.K., Turner, E., Olsen, N., Fazio, S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003), 2407–2415.
44. Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 (2001), 2331–2337.
45. Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramon, E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018.
46. Diz-Kucukkaya, R., Hancer, V.S., Artim-Esen, B., Pekcelen, Y., Inanc, M., The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis 29 (2010), 303–309.
47. Berman, H., Ugarte-Gil, M.F., Espinosa, G., Tassies, D., Monteagudo, J., Reverter, J.C., et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. Clin Exp Rheumatol 31 (2013), 926–932.
48. Gustafsson, J.T., Gunnarsson, I., Kallberg, H., Pettersson, S., Zickert, A., Vikerfors, A., et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus Erythematosus. Ann Rheum Dis 74 (2015), 1537–1543.
49. Sciascia, S., Bertolaccini, M.L., Roccatello, D., Khamashta, M.A., Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis 72 (2013), 142–143.
50. Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M.A., Bertolaccini, M.L., GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52 (2013), 1397–1403.
51. Zuily, S., de Laat, B., Mohamed, S., Kelchtermans, H., Shums, Z., Albesa, R., et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 54 (2015), 2071–2075.